Country: United States
Language: English
Source: NLM (National Library of Medicine)
DESLORATADINE (UNII: FVF865388R) (DESLORATADINE - UNII:FVF865388R)
Sandoz Inc
DESLORATADINE
DESLORATADINE 5 mg
PRESCRIPTION DRUG
Abbreviated New Drug Application
DESLORATADINE- DESLORATADINE TABLET SANDOZ INC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE DESLORATADINE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DESLORATADINE TABLETS. DESLORATADINE TABLETS FOR ORAL USE INITIAL U.S. APPROVAL: 2001 RECENT MAJOR CHANGES Contraindications (4) 04/2014 INDICATIONS AND USAGE DESLORATADINE TABLETS IS AN H -RECEPTOR ANTAGONIST INDICATED FOR: • • • DOSAGE AND ADMINISTRATION DOSAGE (BY AGE): (2) ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OVER: (2) • DOSAGE FORMS AND STRENGTHS • CONTRAINDICATIONS • WARNINGS AND PRECAUTIONS • ADVERSE REACTIONS • TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT SANDOZ, INC., AT 1-800-525-8747 OR FDA AT 1-800-FDA- 1088 OR www.fda.gov/medwatch USE IN SPECIFIC POPULATIONS • • SEE 17 FOR PATIENT COUNSELING INFORMATION. REVISED: 3/2015 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Seasonal Allergic Rhinitis 1 SEASONAL ALLERGIC RHINITIS: relief of nasal and non-nasal symptoms in patients 12 years of age and older. (1.1) PERENNIAL ALLERGIC RHINITIS: relief of nasal and non-nasal symptoms in patients 12 years of age and older. (1.2) CHRONIC IDIOPATHIC URTICARIA: symptomatic relief of pruritus, reduction in the number of hives, and size of hives in patients 12 years of age and older. (1.3) Desloratadine tablets - one 5 mg tablet once daily Desloratadine Tablets - 5 mg (3) Hypersensitivity (4, 6.2) Hypersensitivity reactions including rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis have been reported. In such cases, stop desloratadine tablets at once and consider alternative treatments. (5.1) The most common adverse reactions (reported in ≥2% of adult and adolescent patients with allergic rhinitis and greater than placebo) were pharyngitis, dry mouth, myalgia, fatigue, somnolence, dysmenorrhea. (6.1) Renal impairment: dosage adjustment is recommended (2.5, 8.6, 12.3) Hepatic impairment: dosage adjustment is recommended Read the complete document